Back to Network
4
Shared Docs
4
Same-Page
4 / 4
Mentions
Document Mentions (4 shared documents)
2 mentions1 same-page
Page ?Same page
ig Center for Cancer Genetics and 'Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nenvak's help. Vogelstein and the PED designed a mathematical
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific. inhibitor drugs to fight cancer has been growing in popularity around the wor
2 mentions1 same-page
Page ?Same page
ig Center for Cancer Genetics and 'Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nenvak's help. Vogelstein and the PED designed a mathematical
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific. inhibitor drugs to fight cancer has been growing in popularity around the wor
2 mentions1 same-page
Page ?Same page
ig Center for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nowak's help, EFTA00583237 Vogelstein and the PED designed a
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific, inhibitor drugs to fight cancer has been growing in popularity around the wor
Sponsored
2 mentions1 same-page
Page ?Same page
wig Ccntcr for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nowak's help. Vogelstein and the PED designed a mathematical m
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific. inhibitor drugs to fight cancer has been growing in popularity around the wor
Sponsored
Mutual Connections (16)
Entities connected to both Vogelstein and The Final Frontier
Martin Nowak
PERSON5 w/ Vogelstein·4 w/ The
the Program for Evolutionary Dynamics
ORGANIZATION4 w/ Vogelstein·4 w/ The
Johns Hopkins University School of Medicine
ORGANIZATION4 w/ Vogelstein·4 w/ The
the National Institute of Cancer
ORGANIZATION4 w/ Vogelstein·4 w/ The
Jeffrey Epstein
PERSON4 w/ Vogelstein·4 w/ The
Massachusetts General
ORGANIZATION3 w/ Vogelstein·3 w/ The
BV
Bert Vogelstein
PERSON3 w/ Vogelstein·3 w/ The
TG
the lYinzetor of the Ludwig Center for Cancer Genetics
PERSON2 w/ Vogelstein·2 w/ The
NE
Nenvak
PERSON2 w/ Vogelstein·2 w/ The
the Journal of Oncology
ORGANIZATION2 w/ Vogelstein·2 w/ The
Johns Hopkins
ORGANIZATION2 w/ Vogelstein·2 w/ The
Journal of Oncology
ORGANIZATION2 w/ Vogelstein·2 w/ The
a Biology and Mathematics
ORGANIZATION2 w/ Vogelstein·2 w/ The
Johns I Iopkins
ORGANIZATION2 w/ Vogelstein·2 w/ The
trials pandit&
ORGANIZATION2 w/ Vogelstein·2 w/ The
ET
EGER TX
PERSON2 w/ Vogelstein·2 w/ The